3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Multiple Myeloma
17
Recurrence
9
Lymphoma, Large B-Cell, Diffuse
7
Endometrial Neoplasms
4
Lymphoma, T-Cell, Peripheral
3
Glioblastoma
3
Colorectal Neoplasms
3
Sarcoma
2
Primary Myelofibrosis
2
Neoplasms
2
Melanoma
2
Lymphoma, T-Cell, Cutaneous
2
Carcinoma, Squamous Cell
2
Waldenstrom Macroglobulinemia
1
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Richter's Transformation
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neoplasms, Plasma Cell
1
Neoplasms by Site
1
Myeloproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
ruxolitinib
21
Azacitidine
5
ponatinib
4
parsaclisib
4
nilotinib
4
itacitinib
4
anagrelide
3
Phlebotomy
3
Imatinib Mesylate
3
INCB039110
3
Aspirin
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
venetoclax
2
pemigatinib
2
luspatercept
2
imetelstat
2
givinostat hydrochloride
2
givinostat
2
fedratinib
2
asciminib
2
INCB057643
2
Gemcitabine
2
GRN163L peptide
2
spartalizumab
1
sonidegib
1
selinexor
1
sabatolimab
1
rucaparib
1
pembrolizumab
1
navitoclax
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Myeloproliferative Disorders
×
selinexor
×
Clear all
NCT04562389
2026-04-09
SENTRY
Karyopharm Therapeutics Inc
Phase 3
Active not recruiting
353 enrolled